Approval · Notice of Compliance 20138 · 2017
RISPERDAL CONSTA: Notice of Compliance 20138
Issued December 7, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20138
- Date
- December 7, 2017
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to package labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RISPERDAL CONSTA | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE 15.5 MG per VIAL
- RISPERIDONE 29.7 MG per VIAL
- RISPERIDONE 44.1 MG per VIAL
- RISPERIDONE 57.8 MG per VIAL